It was not so long ago that the number of publicly-listed psychedelic businesses stood at zero. Over the last three years, numerous psychedelic drug developers and related companies have debuted on both American and Canadian exchanges, rapidly creating a multibillion dollar market. However, the path from drug discovery to approval is long, and the confidence of the market has ebbed since its peak in 2021, and much work (and fundraising) still remains to be done. Join us to hear reflections and predictions from psychedelic industry executives, investors, and analysts about the early days of psychedelic public companies.